Swiss pharmaceutical giant Roche has reached a major agreement to acquire the U.S.-based gene therapy company Spark Therapeutics in an all-cash deal valued at $4.3 billion. Under the terms of the deal, Roche will purchase 100% of Spark Therapeutics for $114.50 per share. This acquisition is a strategic move to expand Roche’s capabilities in the […]
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series B financing round. The round was led by Viking Global Investors, with participation from notable investors including ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pfizer […]
